Abstract
Background
miR-200a-3p is involved in the progression of malignant behavior in various tumors, and its mechanism of action in endometrial cancer is speculated to be related to epithelial-mesenchymal transition (EMT). Therefore, this study explored the metastatic mechanism of miR-200a-3p and EMT in endometrial cancer, with the aim of identifying potential therapeutic targets.
Methods
qRT-PCR was used to analyze miR-200a-3p expression in HEC-1B and Ishikawa cell lines. The cell proliferation assay, transwell assay, and cell scratch test were used to assess changes in the malignant phenotypes of cells after regulating miR-200a-3p expression. Changes in EMT-related protein zinc finger E-box binding homeobox 1 (ZEB1) were detected after regulating miR-200a-3p expression. An endometrial carcinoma transplantation mouse tumor model was constructed, and multiple EMT-related proteins were examined.
Results
The expression of miR-200a-3p and ZEB1 in the endometrial cancer cell lines was higher than in normal endometrial epithelial cell lines (P < 0.05). After silencing miR-200a-3p, the expression of EMT-related protein ZEB1 increased, indicating a negative correlation. Simultaneously, the proliferation, invasion, and metastasis of endometrial cancer cells were significantly enhanced. After miR-200a-3p overexpression, the corresponding malignant phenotype was reversed (P < 0.05). In in vivo experiments, the degree of tumor malignancy and the expression level of EMT-related proteins were significantly reduced in the miR-200a-3p mimic group (P < 0.05).
Conclusion
This study found that miR-200a-3p is a promising target, regulating the EMT process and promoting endometrial cancer progression.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
In recent years, the overall incidence of endometrial cancer and incidence in younger ages have increased [1]. According to 2020 statistics from the International Agency for Research on Cancer (IARC), the global number of new cases of endometrial cancer reached 417,367. It is second only to cervical cancer incidence, ranking sixth in the incidence of female malignant tumors, and thus seriously threatens the lives and health of women [2]. IARC data revealed that the number of deaths due to endometrial cancer was nearly 100,000, with distant metastasis being the leading cause of death [3]. The five-year survival rate of patients with distant metastasis was reported to be only 17% [4]. Despite continuous improvements in surgical skills in recent years, the mortality rate of endometrial cancer patients with distant metastases has not decreased [5]. In the era of personalized medicine, it is necessary to determine the best treatment plan for each patient's specific situation. The introduction of molecular/genomic mapping will help to tailor the most appropriate treatment, especially in advanced/metastatic setting, where molecular characterization provides important information on the most appropriate treatment [6].Therefore, exploring the distant metastasis mechanism of endometrial cancer is imperative. The results could provide potential targets for clinical adjuvant therapy.
Abnormal characterization of microRNA is closely associated with the occurrence and development of tumors and is involved in various pathophysiological processes [7, 8]. miR-200a-3p is a miR-200a family member and exists within the genetic spectrum of various tumors. It targets the 3’UTR non-coding region to regulate the tumor-promoting or tumor-inhibiting effects of downstream targets [9, 10]. WU [11] demonstrated that miR-200a-3p enhanced the proliferation and metastasis of non-small cell lung cancer cells by targeting SOX17 downregulation. Lv [12]observed that SNHG10 could up-regulate BIN1 by sponging miR-200a-3p through tumor suppression in epithelial ovarian cancer (EOC), thereby inhibiting the occurrence of EOC and epithelial-mesenchymal transition (EMT). By inhibiting the expression of miR-200a-3p, the expression of EMT-related targets, such as N-cadherin, Vimentin and Alpha-SMA, can be significantly enhanced, while the expression of E-Cadherin can be decreased. However, no study has elucidated its mechanism of action in endometrial cancer.
Our research group explored the role of miR-200a-3p in endometrial cancer to identify possible downstream regulatory targets and clarify the mechanism causing distant metastasis in endometrial cancer. Recent studies reported that EMT, a complex biological process, could promote cancer progression and distant metastasis [13, 14]. EMT process inhibitors can significantly inhibit the invasion and metastasis of breast, bladder, and other tumors [15, 16]. Therefore, we explored the correlation between miR-200a-3p and EMT. Zinc finger E-box binding homeobox 1 (ZEB1) is closely related to EMT and has noticeable phenotype changes after regulating miR-200a-3p [17].
ZEB1 is a zinc finger homologous transcription factor family member located on chromosome 10 (10p11.2). It can promote tumor cell activity through EMT and enhance the migration and invasion of tumor cells. ZEB1 can reconstruct the tumor microenvironment and plays a synergistic role as a multi-effect transcription factor [18]. Colangelo [19]reported that ZEB1 enhanced the aggressiveness of colorectal cancer cells by promoting the EMT process and driving the pathological process behind the colorectal cancer malignant phenotype. Wu HT also revealed that ZEB1 had mesenchymal properties, increasing the proliferation, metastasis, and drug resistance of breast cancer cells [20]. Diepenbruck [21]incorporated microRNA sequencing and functional verification in the mouse model of metastatic breast cancer to determine the function of miR-1199-5p and ZEB1 in the double-negative feedback loop, thereby controlling the occurrence of EMT and tumor metastasis. ZEB1 is similar to E-Cadherin in the EMT process and is the target gene of miR-200a-3p. miR-200a-3p can directly target part of ZEB1, which has the potential to be used in the therapy of endometrial cancer.
Therefore, the current study selected miR-200a-3p to investigate the role of abnormal microRNA expression in endometrial cancer and the resulting tumor malignancy. The study attempted to clarify the mechanism of miR-200a-3p in endometrial cancer invasion and metastasis and other EMT-related malignant phenotypes through in vitro and in vivo experiments (Fig. 1) to provide more novel targeted treatment options for patients with distant metastases of advanced endometrial cancer.
2 Materials and methods
2.1 Cell lines and cell culture
The Department of Epidemiology, School of Public Health, Harbin Medical University donated the endometrial cancer cell lines (HEC-1B and Ishikawa) and the normal endometrial hEEC cell line. HEC-1B cells were cultured in Minimal Essential Medium (MEM), and Ishikawa and hEECs were cultured in Dulbecco’s modified Eagle medium (DMEM). Fetal bovine serum (10%) and 1% cyan-streptomycin were added to each medium. Insulin (10 μg/mL) and endothelial growth factor (5 ng/mL) were added to DMEM used for culturing hEECs. All cells were cultured in a cell incubator at 37 ℃ and 5% CO2.
2.2 Quantitative real-time PCR
Total RNA was extracted using an animal RNA extraction kit (Beyotime, R0026). PrimeScript™ RT Master Mix kit (Takara, RR036A) and 2 × SYBR Green qPCR Master Mix (Bimake, B21203) were used to perform quantitative fluorescence PCR. The primer sequences of miR-200a-3p and ZEB1 are shown in Supplementary Table 1. The reaction conditions were 95 ℃ for 15 s, 60 ℃ for 30 s, and 72 ℃ for 30 s for 40 cycles.
2.3 Western blots
Nuclear proteins were extracted with a nucleoprotein extraction kit (Solarbio, R0050). The BCA method was used analyze protein concentrations by comparison with a standard curve. Sodium dodecyl sulfate-gel electrophoresis was performed after the appropriate loading amount was determined. Then, the membrane was transferred, closed, and incubated with ZEB1 monoclonal antibody (ABclonal, A21794) at 4 ℃ overnight. Finally, the secondary antibody was added and incubated for 1 h. The protein bands were observed using ECL reagent.
2.4 Cell transfection with miR-200a-3p-overexpressing and knocked down microRNA mimic
The miR-200a-3p-overexpressing mimic (miR-200a-3p mimic), miR-200a-3p knocked down mimic (miR-200a-3p inhibitor), and control blank (NC) were developed by GenePharma, China. About 80% of the fused cells were transfected, and Lipo3000 was diluted using opti-MEM. Transfection efficiency was measured after 72 h of transfection.
2.5 Cell proliferation, invasion, and metastasis experiments
The proliferation of endometrial cancer cells transfected with miR-200a-3p inhibitor and mimic were measured using a CCK8 kit (Beyotime, C0037). After cell lamination using 96-well plates, miR-200a-3p knockdown and overexpressed mimic were transfected with Lipo3000 reagent for further culture. Then, 10 μL of CCK8 solution was added to each well, and absorbance was measured at 450 nm. Cells in the logarithmic growth stage were cultured without serum starvation and inoculated into a transwell chamber at a density of 4 × 105 cells. After staining and fixation, cell invasion was observed under a microscope. In the cell scratch experiment, six-well plates helped in cell planking, and 5 × 105 endometrial cancer cells were added to each hole for the 24 h culture.
2.6 Animal experiment
Fifteen five-week-old BALB/C female nude mice weighing 20–25 g were purchased from Charles River, China, and grouped into miR-200a-3p inhibitor, mimic, and blank groups (n = 5). HEC-1B endometrial cancer cells were transfected with the miR-200a-3p inhibitor, mimic, and blank control, and 2 × 106 cells were implanted subcutaneously in each mouse. All mice were provided free access to water and food and maintained at 20 ℃ and 50% constant humidity. The mice were observed daily. The mice were euthanized after two weeks of tumor formation, and the tumors were extracted and weighed for further experiments.
2.7 Immunohistochemistry
Mice tumor grafted tissues were embedded in paraffin, sectioned, and dewaxed in xylene, hydrated using different ethanol concentrations, and repaired with the H2O2 antigen. Finally, the tissues were incubated with ZEB1 primary and secondary antibodies (ABclonal, A5600) and stained with DAB and hematoxylin. and the tablets were sealed after dehydration for observation. Then, the degree of staining was quantified and photographed using a microscope.
2.8 Enzyme-linked immunosorbent assay
The fibronectin (FN) and Snail protein enzyme-linked immunosorbent assay (ELISA) kits were purchased from BYabscience, China. The enzyme-labeled reagent, chromogenic agent, and the reaction terminator in the kit were used for corresponding incubation at 37℃. The absorption value was determined at 450 nm after reaction termination.
2.9 Statistical analysis
SPSS 19 was used for all statistical analyses. The data are expressed as the mean ± standard deviation. The t-test was used to analyze statistical differences between the control and experimental groups, and P-values of < 0.05 were considered statistically significant. Each experiment was repeated three times.
3 Results
3.1 miR-200a-3p and ZEB1 are highly expressed in endometrial cancer cell lines
The qRT-PCR results revealed that miR-200a-3p expression was significantly up-regulated in the HEC-1B and Ishikawa endometrial epithelial cell lines compared to the normal hEEC endometrial epithelial cell line (Fig. 2A; **P < 0.05). This was consistent with the expression of bioinformatics database analysis in endometrial cancer patients (Fig. S1). ZEB1 mRNA expression was higher in the endometrial cancer cell lines than in the normal endometrial epithelial cell line (Fig. 2B; **P < 0.05). The Western blot results revealed that ZEB1 protein expression levels were significantly higher in the endometrial cancer cell lines than in normal endometrial epithelial cells (Fig. 2C, D; **P < 0.05).
3.2 MiR-200a-3p is negatively associated with ZEB1 expression in endometrial cancer
qRT-PCR was used to verify the successful knockdown and overexpression of miR-200a-3p in HEC-1B and Ishikawa endometrial cancer cell lines (Fig. S2A-B; **P < 0.05). qRT-PCR was also used to analyze changes in ZEB1 in the HEC-1B endometrial cancer cell line at the mRNA expression level after knocking down and overexpressing miR-200a-3p. The results indicated that the expression level of ZEB1 in the HEC-1B endometrial cancer cell line was significantly elevated after the knockdown and overexpression of miR-200a-3p (Fig. 3A; **P < 0.05). The ZEB1 content change at the protein level was consistent with the mRNA level (Fig. 3B, C; **P < 0.05) after verifying the miR-200a-3p regulation with western blot, with similar results in the Ishikawa cell line (Fig. 3D–F; **P < 0.05). The same correlations were seen between the two cell lines using bioinformatics analysis (Fig. S2C). Therefore, miR-200a-3p was negatively correlated with ZEB1 expression in endometrial cancer patients.
3.3 Knockdown of miR-200a-3p promotes the proliferation, invasion, and migration of endometrial cancer cells
The transwell assay results revealed that the invasion ability of HEC-1B endometrial cancer cells was significantly enhanced in the miR-200a-3p knockdown group. In contrast, the overexpressing group had a lower invasion ability than the control group (Fig. 4A, B). The CCK8 method helped verify the miR-200a-3p knockdown and overexpression effects on the proliferative ability of endometrial cancer cells. The results indicated that the proliferative ability of endometrial cancer cells was increased after miR-200a-3p knockdown and significantly less after overexpression (Fig. 4C). Finally, the cell scratch assay was used to observe changes in cell migration ability after miR-200a-3p knockout. The results depicted the enhanced migration ability of HC-1B endometrial cancer cells within the miR-200a-3p knockout group (Fig. 4D. The same changes in the invasion phenotype were obtained by repeating the test in the Ishikawa endometrial cancer cell line (Fig. S3).
3.4 Overexpression of miR-200a-3p reduces tumorigenicity in mice
We successfully constructed a transplanted mouse tumor model using the HEC-1B endometrial cancer cell line based on the above experimental results. The results indicated that the tumor size and weight of mice transfected with the miR-200a-3p-overexpressing mimic were significantly smaller than the control group (Fig. 5A, B). qRT-PCR and Western blots were used to analyze ZEB1 expression at the mRNA and protein levels in mouse subcutaneous tumors. The results were consistent with our in vitro experimental results in endometrial cancer cell lines.
After regulating miR-200a-3p, ZEB1 showed the opposite expression (Fig. 5C, D). Immunohistochemistry was used to detect changes in ZEB1 expression in tumor tissues with miR-200a-3p overexpression and knockdown. The results also suggested that ZEB1 was primarily located in the nucleus (Fig. S4). Finally, ELISA was used to determine the changes in fibronectin (FN) and SNAIL proteins after regulation to clarify the other EMT-related protein changes in mice tumors after miR-200a-3p overexpression. FN and SNAlL are recognized as EMT-related proteins, depicting the enhanced invasion and metastasis ability of tumor cells [22, 23]. The experimental results indicated that the expression of FN and SNAIL in tumors in the miR-200a-3p-overexpressing group was decreased. In contrast, the expression in the miR-200a-3p-knockout group was high (Fig. 5E-F). Therefore, in vivo experiments in mice demonstrated that miR-200a-3p-overexpression decreased tumorigenicity and attenuated the malignant phenotype of endometrial cancer.
4 Discussion
Endometrial cancer has a gradually rising trend of disease load [24]. Despite the combined treatment regimen of standardized surgery with chemotherapy, metastasis and recurrence still occur in many patients. Therefore, exploring the metastatic mechanism of advanced metastatic endometrial cancer and developing more targeted drugs against efficient targets can improve the survival of endometrial cancer patients.
Recently, some scholars conducted relevant studies on the role of miR-200a-3p in non-small cell lung cancer [25], cervical cancer [26], bladder cancer [27], and other tumors, establishing the regulatory mechanism of miR-200a-3p in these tumors. The results showed different mechanisms of action and phenotypic effects of miR-200a-3p in different tumors. We conducted a preliminary exploration of the regulatory role of miR-200a-3p in endometrial cancer and found a significantly high expression level of miR-200a-3p in endometrial cancer cell lines compared to normal endometrial epithelial cells. Simultaneously, knockdown and overexpression regulation of miR-200a-3p depicted a significant decrease in the proliferation, invasion, and migration of endometrial cancer cells after miR-200a-3p up-regulation. In contrast, the corresponding malignant phenotype was significantly enhanced after the down-regulation of miR-200a-3p. Therefore, this preliminary study suggests that miR-200a-3p regulation can negatively regulate endometrial cancer metastasis. Relevant studies reported that the metastasis mechanism of endometrial cancer is closely associated with EMT [28]. EMT is significantly correlated with tumor cell dryness, metastasis potential, immune escape, and treatment resistance [29, 30]. ZEB1 is an efficient transcription factor in the EMT process [31] and is essential for activating the invasion and metastasis phenotypes of endometrial cancer. Therefore, our study explored the correlation between miR-200a-3p and ZEB1. ZEB1 was highly expressed in the endometrial cancer cell lines, consistent with the results of previous studies. Additionally, ZEB1 expression was opposite to miR-200a-3p after its regulation, depicting a negative correlation between them. The mice experiments proved that EMT-related proteins like ZEB1 were significantly elevated after miR-200a-3p knockout. Therefore, miR-200a-3p could regulate MET and indirectly act on the corresponding ZEB1 targets to promote the invasion and metastasis of endometrial cancer. A corresponding mechanistic axis could exist between miR-200a-3p and ZEB1 or competitively bind with other targets [32, 33] to regulate the progression of malignancy. Our research group will explore the specific mechanism producing this effect further.
The corresponding inhibitors were combined with various current efficient delivery systems after elucidating the mechanism of miR-200a-3p in promoting the progression of endometrial cancer. Thus, new delivery materials were developed that could effectively reduce endometrial cancer malignancy and the possibility of distant metastasis while prolonging the survival of patients. Zhou [34] transferred miR-21-5p inhibitors into a mouse lung cancer model using a novel gene delivery technology and conducted ultrasound-targeted microbubble destruction to significantly inhibit lung cancer progression. Ou [35] utilized a graphene oxide-polyethylenimine complex to efficiently deliver miR-214 inhibitors and inhibit the invasion and metastasis of oral squamous cell carcinoma. Liang [36] targeted engineered exosomes to colon cancer cells to deliver a combination of miR-21 inhibitors and 5-fluorouracil, which reversed drug resistance in colon cancer. Liu [37] prepared nanobubbles for loading programmed death ligand 1 (PD-L1) antibody and the miR-424 gene, which significantly enhanced the immunotherapy effect of hepatocellular carcinoma and improved anti-tumor effects. Therefore, the EMT-promoting mechanism of miR-200a-3p and ZEB1 can be used to inhibit the metastatic potential of endometrial cancer, with corresponding effects in immunotherapy and chemotherapy resistance.
This study preliminarily explored the role of miR-200a-3p in endometrial cancer and demonstrated its regulatory role in the EMT process, including ZEB1 expression, which can provide a promising target for treating metastatic endometrial cancer.
Data availability
All relevant data are within the manuscript and its additional files.
Abbreviations
- EMT:
-
Epithelial–mesenchymal transition
- ZEB1:
-
Zinc finger E-box binding homeobox 1
- IARC:
-
International Agency for Research on Cancer
- UTR:
-
Untranslated region
- EOC:
-
Epithelial ovarian cancer
- FN:
-
Fibronectin
- UTMD:
-
Ultrasound-targeted microbubble destruction
- PD-L1:
-
Programmed death ligand 1
References
Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412–28. https://doi.org/10.1016/S0140-6736(22)00323-3.
Sung H, Ferlay J, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Vicky M, Helen MacKay, Isabelle R-C, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7(1):88. https://doi.org/10.1038/s41572-021-00324-8.
Yen TT, Wang TL, Fader AN, et al. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26–35. https://doi.org/10.1097/PGP.0000000000000585.
Ying X, Che X, Wang J, et al. CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer. J Cancer. 2021;12(8):2206–15. https://doi.org/10.7150/jca.51139.
Di Donato V, Giannini A, Bogani G. Recent advances in endometrial cancer management. J Clin Med. 2023;12(6):2241. https://doi.org/10.3390/jcm12062241.
Mockly S, Houbron É, Seitz H. A rationalized definition of general tumor suppressor microRNAs excludes miR-34a. Nucleic Acids Res. 2022;50(8):4703–12. https://doi.org/10.1093/nar/gkac277.
Wang X, Holgado BL, Ramaswamy V, et al. miR miR on the wall, who’s the most malignant medulloblastoma miR of them all? Neuro Oncol. 2018;20(3):313–23. https://doi.org/10.1093/neuonc/nox106.
Guo-Liang H, Sun Jiancong Lu, Yan, et al. MiR-200 family and cancer: From a meta-analysis view. Mol Aspects Med. 2019;70:57–71. https://doi.org/10.1016/j.mam.2019.09.005.
Shi C, Yang Y, Zhang L, et al. MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.Onco Targets Ther. 2019; 12:8329–8338. https://doi.org/10.2147/OTT.S220339.
Wu X, Liu H, Zhang M, et al. miR-200a-3p promoted cell proliferation and metastasis by downregulating SOX17 in non-small cell lung cancer cells. J Biochem Mol Toxicol. 2022;36(6): e23037. https://doi.org/10.1002/jbt.23037.
Lv W, Jia Y, Wang J, et al. Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p. Cell Death Discov. 2022;8(1):60. https://doi.org/10.1038/s41420-022-00825-9.
Brabletz T, Kalluri R, Nieto M, et al. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–34. https://doi.org/10.1038/nrc.2017.118.
Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216(5):1016–26. https://doi.org/10.1084/jem.20181827.
Hasmim M, Berchem G, Janji B. A role for EMT in CD73 regulation in breast cancer. Oncoimmunology. 2022;11(1):2152636. https://doi.org/10.1080/2162402X.2022.2152636.
Schulz A, Gorodetska I, Behrendt R, et al. Linking NRP2 with EMT and chemoradioresistance in bladder cancer. Front Oncol. 2020;9:1461. https://doi.org/10.3389/fonc.2019.01461.
Caramel J, Ligier M, Puisieux A. Pleiotropic roles for ZEB1 in cancer. Cancer Res. 2018;78(1):30–5. https://doi.org/10.1158/0008-5472.CAN-17-2476.
Perez-Oquendo M, Gibbons DL. Regulation of ZEB1 function and molecular associations in tumor progression and metastasis. Cancers (Basel). 2022;14(8):1864. https://doi.org/10.3390/cancers14081864.
Colangelo T, Carbone A, Mazzarelli F, et al. Loss of circadian gene timeless induces EMT and tumor progression in colorectal cancer via Zeb1-dependent mechanism. Cell Death Differ. 2022;29(8):1552–68. https://doi.org/10.1038/s41418-022-00935-y.
Wu HT, Zhong HT, Li GW, et al. Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 2020;18(1):51. https://doi.org/10.1186/s12967-020-02240-z.
Diepenbruck M, Tiede S, Saxena M, et al. miR-1199-5p and Zeb1 function in a double-negative feedback loop potentially coordinating EMT and tumour metastasis. Nat Commun. 2017;8(1):1168. https://doi.org/10.1038/s41467-017-01197-w.
Zou Y, Wang Y, Wen X, et al. A DNA aptamer targeting cellular fibronectin rather than plasma fibronectin for bioimaging and targeted chemotherapy of tumors. Adv Funct Mater. 2022;32:2205002. https://doi.org/10.1002/adfm.202205002.
Hashemi M, Hajimazdarany S, Mohan CD, et al. Long non-coding RNA/epithelial-mesenchymal transition axis in human cancers: tumorigenesis, chemoresistance, and radioresistance. Pharmacol Res. 2022;186:106535. https://doi.org/10.1016/j.phrs.2022.106535.
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90. https://doi.org/10.1097/CM9.0000000000002108.
Yu J, He X, Fang C, et al. MicroRNA-200a-3p and GATA6 are abnormally expressed in patients with non-small cell lung cancer and exhibit high clinical diagnostic efficacy. Exp Ther Med. 2022;23(4):281. https://doi.org/10.3892/etm.2022.11210.
Chen H, Gu L, Zhang M, et al. Interaction of miR-200a-3p with YAP regulates cell proliferation and metastasis differentially in HPV-positive and HPV-negative cervical cancer cells. BMC Cancer. 2022;22(1):1039. https://doi.org/10.1186/s12885-022-10118-0.
Wan P, Chen Z, Huang M, et al. miR-200a-3p facilitates bladder cancer cell proliferation by targeting the A20 gene. Transl Androl Urol. 2021;10(11):4262–74. https://doi.org/10.21037/tau-21-941.
Gelissen JH, Huang GS. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer. Front Oncol. 2022;12:914405. https://doi.org/10.3389/fonc.2022.914405.
Pastushenko I, Brisebarre A, Sifrim A, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556(7702):463–8. https://doi.org/10.1038/s41586-018-0040-3.
Romeo E, Caserta CA, Rumio C, et al. The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system. Cells. 2019;8(5):460. https://doi.org/10.3390/cells8050460.
Lindner P, Paul S, Eckstein M, et al. EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells. Cell Death Dis. 2020;11(2):147. https://doi.org/10.1038/s41419-020-2340-4.
Tan S, Kang Y, Li H, et al. circST6GALNAC6 suppresses bladder cancer metastasis by sponging miR-200a-3p to modulate the STMN1/EMT axis. Cell Death Dis. 2021;12(2):168. https://doi.org/10.1038/s41419-021-03459-4.
Wei S, Wang K, Huang X, et al. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019;33:2058738419859699. https://doi.org/10.1177/2058738419859699.
Zhou X, Liu H, Pang Y, et al. UTMD-mediated delivery of miR-21-5p inhibitor suppresses the development of lung cancer. Tissue Cell. 2022;74:101719. https://doi.org/10.1016/j.tice.2021.101719.
Ou L, Sun T, Liu M, et al. Efficient miRNA Inhibitor Delivery with Graphene Oxide-Polyethylenimine to Inhibit Oral Squamous Cell Carcinoma. Int J Nanomedicine. 2020;15:1569–83. https://doi.org/10.2147/IJN.S220057.
Liang G, Zhu Y, Ali DJ, et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnology. 2020;18(1):10. https://doi.org/10.1186/s12951-019-0563-2.
Liu Y, Xie Q, Ma Y, et al. Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice. Int J Pharm. 2022;629:122352. https://doi.org/10.1016/j.ijpharm.2022.122352.
Acknowledgements
This work was supported by the Natural Science Foundation of China (No. 82073239).
Author information
Authors and Affiliations
Contributions
Ying Ma, Tuo Dong and Xiuwei Chen contributed to the study conception and design; Material preparation, data collection and analysis were performed by Ying Ma, Yiru Wang and Can Wang; The first draft of the manuscript was written by Ying Ma and Yan Wang; Jingshu Hu and Zexue Zhang commented on previous versions of the manuscript; Tuo Dong and Xiuwei Chen read and approved the final manuscript. Acquisition of the financial support for the project leading to this publication was by Xiuwei Chen.
Corresponding authors
Ethics declarations
Ethics approval and content to participate
This project has been approved by the ethics committee of the Cancer Hospital of Harbin Medical University. The animal experimental research involved in this project complies with the ethical guidelines of the Cancer Hospital of Harbin Medical University, the ethical guidelines of the People's Republic of China for Animal experiments, and the Basel Declaration. The maximal tumor size permitted by the ethics committee is less than 2000 mm3 and the maximal diameter is less than 1.5 cm. The ethics committee confirmed that the size and diameter of the tumors in this study did not exceed the requirements.
Competing interests
The authors declare no competing financial interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ma, Y., Wang, Y., Wang, C. et al. miR-200a-3p promotes the malignancy of endometrial carcinoma through negative regulation of epithelial-mesenchymal transition. Discov Onc 15, 243 (2024). https://doi.org/10.1007/s12672-024-01106-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12672-024-01106-w